Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation

In a trial involving patients with COPD and type 2 inflammation shown by elevated blood eosinophil counts, treatment with dupilumab reduced disease exacerbation and improved lung function.

​In a trial involving patients with COPD and type 2 inflammation shown by elevated blood eosinophil counts, treatment with dupilumab reduced disease exacerbation and improved lung function.   The New England Journal of Medicine: Search Results in Allergy/Immunology